Koninklijke Philips N.V. research snapshot
PHG AI stock analysis as of the August 2, 2026 data cutoff reads Koninklijke Philips as a healthcare technology turnaround whose Q2 2026 report, published July 27, 2026, combined 4% comparable sales growth with a 16.4% adjusted EBITA margin that included a one-time US tariff refund benefit of effectively 4.2%. The stock closed at $26.30 on July 31, 2026 with a market capitalization near $25.71 billion, re-verified during this full refresh as $26.30 times 977.43 million shares, close to the $25.57 billion reported by StockAnalysis.com with 0.53% deviation. Excluding the tariff refund, the underlying adjusted margin was about 12.2%, down roughly 20 basis points year over year, and comparable order intake declined 1% because several large Connected Care orders shifted into the third quarter, ending six consecutive quarters of order growth. The market sold the stock down as much as 11% on the order decline before it recovered to $26.30. Management reiterated full-year comparable sales growth of 3% to 4.5%, raised adjusted EBITA margin guidance to 13.5% to 14.0% and free cash flow guidance to EUR 1.5 to 1.7 billion to reflect the refund, and guided underlying (ex-refund) 2026 margin of 12.5% to 13.0% and underlying free cash flow of EUR 1.3 to 1.5 billion. The PHG AI stock forecast is scenario-based, not a precise price prediction, and this page is informational research rather than investment advice.
Current price
$26.30
Market cap
$25.71 billion
AI score
60 / 100
Rating
Turnaround with tariff refund benefit, order timing and China execution risk
Trend status
Below the 50-day and 200-day moving averages after the post-earnings pullback
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Philips sells diagnostic imaging, image-guided therapy, patient monitoring, enterprise informatics, sleep and respiratory care, and personal health products to hospitals, clinicians, patients, and consumers. | High |
| Moat | The moat comes from regulated products, installed systems, clinical workflow integration, service relationships, patents, and global distribution. It is real but contested by larger medtech peers and requires quality execution. | Medium-high |
| Management | CEO Roy Jakobs is executing focused segment strategies, platform innovation, productivity, and quality improvement. Q2 2026 delivered EUR 132 million in productivity savings and a record order book, but the 1% order decline and a Q4-dependent margin path mean credibility still needs proof. | Medium |
| Financial trend | Q2 2026 group sales were EUR 4.4 billion with 4% comparable growth, income from operations was EUR 609 million including a EUR 186 million US tariff refund, free cash flow was EUR 222 million including the refund, and net debt to adjusted EBITDA improved to 1.8x from 2.2x a year earlier. | High |
| Valuation | At $26.30, financial_rigor.py calculated about 20.1x trailing EPS, 14.23x forward earnings, about 11.2x trailing free cash flow, about 1.97x book value, and a 3.19% dividend yield using current data-provider inputs, in line with StockAnalysis.com statistics. | Medium |
| Technical trend | PHG closed at $26.30 on July 31, 2026, below the 50-day moving average of $26.64 and the 200-day moving average of $27.85 after the post-earnings pullback, with 14-day RSI near 47.63. | Medium |
| Risk level | Risk is high because Respironics-related proceedings including the US Department of Justice investigation, patient safety and quality, tariffs and cost inflation, China centralized procurement, order timing, leverage, and currency can materially affect earnings and valuation. | High |
| AI confidence | High for reported facts and arithmetic that matched across StockAnalysis.com, the Q2 2026 earnings release, and the earnings call. Medium for forecast ranges because legal outcomes, tariff policy, China demand, and medical-device order timing are not reliably predictable from past data. | High data confidence |
| Investment certainty | Medium-low certainty. The recovery is visible and the balance sheet is improving, but a durable investment case needs proof that order intake recovers in Q3 and that underlying margins improve without another tariff refund. | Medium-low |
PHG AI stock forecast
The PHG AI stock forecast uses scenario ranges around the $26.30 July 31 close rather than a point target. A financial_rigor.py three-scenario model using approximately $1.85 implied forward EPS (from the 14.23x forward multiple) produced mechanical three-year values near $41.90 in a bull case, $30.00 in a base case, and $17.40 in a bear case before dividends, currency moves, and execution risk.
$38 to $46
More likely if Q3 order intake recovers as management guides, comparable sales hold in the 3% to 4.5% range, adjusted EBITA margin reaches the 13.5% to 14.0% target including the refund, free cash flow reaches EUR 1.5 to 1.7 billion, China stabilizes, and Respironics costs do not create new material setbacks.
$27 to $33
More likely if Philips delivers gradual underlying margin and cash-flow improvement, the order decline proves to be timing rather than demand, tariffs and cost inflation are mostly offset by productivity, and the market holds the stock near a mid-teens forward earnings multiple.
$15 to $19
More likely if the order decline signals weaker hospital demand, China continues to weaken, cost inflation stays high single digit or accelerates, tariffs persist, Respironics or quality costs rise, or the market loses confidence in the back-loaded Q4 margin step-up and compresses the multiple.
PHG AI technical analysis
PHG AI technical analysis starts from the $26.30 July 31, 2026 close, which is below the 50-day moving average of $26.64 and the 200-day moving average of $27.85 after the post-earnings pullback. StockAnalysis.com listed a 20-day average volume of about 1.37 million shares and RSI of 47.63, while Barchart listed a 14-day historical volatility near 36% and a 9-day ATR near $0.79. These static levels must be refreshed against a live chart before any decision.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $26.30 | StockAnalysis.com listed this regular-session close on July 31, 2026. The August 2 cutoff follows the latest available quote snapshot. |
| Near support | $25.85 to $26.00 | The July 29 and July 31 session lows clustered around $25.46 to $25.91 after the earnings drop, a first nearby downside reference. |
| Deeper support | $23.85 | The 52-week low listed in the quote snapshot was set on July 28, 2026 and is a broader downside reference, not a stop recommendation. |
| Near resistance | $26.64 to $27.00 | The 50-day moving average was $26.64 and Barchart placed the 100-day near $27.00, forming the first overhead zone on any recovery. |
| Higher resistance | $27.85 to $33.44 | The 200-day moving average was $27.85 and the 52-week high was $33.44. A move through the 200-day would need confirmation from volume and fundamentals. |
| Momentum | Neutral | 14-day RSI was near 47.63 on StockAnalysis.com and Barchart, below the neutral 50 line after the pullback. |
| Volume | About 1.37M 20-day average shares | Volume jumped to about 3.1 million shares on July 28, 2026 as the market reacted to Q2 results, so breakouts need volume above the recent average to be credible. |
| Volatility | Moderate beta, high event risk | The listed five-year beta was 0.92 and Barchart showed 14-day historical volatility near 36%, so earnings, legal, regulatory, tariff, and quality headlines can create gap risk beyond a beta measure. |
| Invalidation | Failure below $25.46, then $23.85 | A loss of the late-July swing low followed by a move toward the 52-week low would invalidate a simple recovery setup and extend the downtrend. |
PHG AI trading strategy
The PHG AI trading strategy is a non-personalized framework for a medical-technology turnaround. It should be used with position sizing, refreshed chart data, earnings dates, and independent review of legal and regulatory disclosures.
Monitor whether PHG reclaims the $26.64 to $27.00 resistance zone and then the $27.85 200-day moving average, and confirm the move with updated order intake, margins, and free-cash-flow guidance.
Treat a sustained failure below the late-July swing low, a new quality or litigation shock, a further order decline, or reduced cash-flow guidance as conditions that invalidate the setup.
If PHG revisits the $25.85 to $26.00 area while comparable sales, productivity, and the 2026 outlook remain intact, monitor whether buyers defend the level and rebuild toward the 50-day average.
Do not average down solely because the dividend yield rises. Reassess if the decline is tied to a material Respironics, tariff, China, order, or cash-flow development.
Track comparable sales and order intake by segment, underlying adjusted EBITA margin excluding the tariff refund, free cash flow, net debt and leverage, Q3 and Q4 margin trajectory, China procurement exposure, cost inflation, and all Respironics-related disclosures.
Reduce confidence if margin gains depend mainly on one-time refund benefits or temporary cost actions while revenue, order intake, quality metrics, cash flow, or liability clarity deteriorate.
Investment research summary
Customers pay Philips for regulated medical technology, imaging and image-guided therapy workflow, monitoring as a service, enterprise informatics, sleep and respiratory care, and consumer health products. Revenue combines equipment, leasing, services, software, disposables, and consumer sales.
The moat rests on installed equipment, clinician workflow integration, regulatory know-how, patents, service relationships, and global scale. Its durability depends on product quality, innovation speed, hospital purchasing cycles, and how well it defends against centralized procurement and larger competitors.
The failure path is a recovery that proves too expensive or too slow: new quality or legal costs, Respironics proceedings, order intake that fails to recover, weak China hospital demand, tariffs and high single digit cost inflation, and a Q4 margin step-up that does not arrive, leaving debt and shareholder returns pressured.
Roy Jakobs has centered the plan on focused segment strategies, AI-enabled platforms, productivity, supply chain resilience, and quality. Q2 2026 delivered EUR 132 million in productivity savings and a record equipment order book, but the 1% order decline and a back-loaded margin path mean management quality should be judged by Q3 order recovery and full-year delivery.
Aging populations, clinician shortages, hospital-at-home programs, and demand for productivity support imaging, monitoring, data, and AI-assisted workflows. Tariffs, reimbursement, centralized procurement, and hospital budgets limit how much of that demand becomes profit.
PHG trades near 20x trailing earnings, about 14.2x forward earnings, and near 11x trailing free cash flow with a 3.2% indicated dividend yield and improving leverage at 1.8x net debt to adjusted EBITDA. The margin of safety depends on order intake, underlying margins, and liabilities improving together, not on the one-time refund.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| PHG price | $26.30 at the July 31, 2026 close | StockAnalysis.com quote snapshot | August 2, 2026 |
| Market capitalization | $25.71 billion computed as $26.30 x 977.43 million shares; StockAnalysis.com reported $25.57 billion, a 0.53% deviation | StockAnalysis.com statistics and financial_rigor.py market-cap check | August 2, 2026 |
| Shares outstanding | 977.43 million, up 3.68% year over year | StockAnalysis.com statistics | August 2, 2026 |
| Q2 2026 group performance | Comparable order intake down 1% due to order timing, sales of EUR 4.4 billion with 4% comparable sales growth, income from operations of EUR 609 million including a EUR 186 million US tariff refund, adjusted EBITA margin of 16.4% including a 4.2% refund benefit, operating cash flow of EUR 376 million and free cash flow of EUR 222 million including the refund | Philips Q2 2026 results press release | July 27, 2026 |
| Q2 2026 segment comparable sales | Diagnosis and Treatment up 2%, Connected Care up 2%, Personal Health up 8%; adjusted EBITA margins of 13.9%, 17.8%, and 23.0% respectively, each including a tariff refund benefit of roughly 4.6%, 6.1%, and 5.0% | Philips Q2 2026 results press release and earnings call | July 28, 2026 |
| Q2 2026 underlying margin | About 12.2% adjusted margin excluding the tariff refund, down about 20 basis points year over year, with the full-year underlying outlook unchanged at 12.5% to 13.0% | Philips Q2 2026 earnings call | July 28, 2026 |
| 2026 outlook | Comparable sales growth of 3% to 4.5% reiterated; adjusted EBITA margin raised to 13.5% to 14.0% including about 1% tariff refund benefit from 12.5% to 13.0%; free cash flow raised to EUR 1.5 to 1.7 billion from EUR 1.3 to 1.5 billion; underlying ex-refund margin and free cash flow outlook unchanged | Philips Q2 2026 results press release | July 27, 2026 |
| Q2 2026 productivity | EUR 132 million in savings in the quarter and EUR 258 million year to date, on track to deliver EUR 1.5 billion under the 2026 to 2028 productivity program | Philips Q2 2026 results press release and earnings call | July 28, 2026 |
| Net debt and leverage | Net debt of EUR 5.7 billion at the end of Q2 2026 with net debt to adjusted EBITDA improved to 1.8x from 2.2x in Q2 2025; cash of EUR 1.8 billion | Philips Q2 2026 earnings call | July 28, 2026 |
| FY2025 revenue | EUR 17.834 billion | Philips 2025 Annual Report and StockAnalysis.com financials | August 2, 2026 |
| FY2025 income and cash flow | Income from operations of EUR 1.424 billion, net income of EUR 895 million, and free cash flow of EUR 512 million per the annual report | Philips 2025 Annual Report | August 2, 2026 |
| Respironics-related charges | EUR 209 million in 2025 | Philips 2025 Annual Report | August 2, 2026 |
| Analyst consensus | Hold with an average target of $32.21 across 5 analysts, low $26.75, median $29.50 and high $41 | StockAnalysis.com forecast | August 2, 2026 |
| Recent analyst actions | Deutsche Bank lowered its target to EUR 24 from EUR 25 with a Hold, JPMorgan raised its target to EUR 23.50 from EUR 22.60 with a Neutral, and Bank of America maintained a Hold | StockAnalysis.com forecast and TheFly via TipRanks | July 31, 2026 |
| Valuation check | 20.09x trailing EPS, 14.23x forward earnings, 1.27x sales, 1.95x book value, 11.11x free cash flow, 3.20% dividend yield, EV/EBITDA 9.45 | StockAnalysis.com statistics | August 2, 2026 |
| Technical snapshot | 50-day moving average near $26.64, 200-day near $27.85, 14-day RSI near 47.63, 20-day average volume near 1.37 million shares | StockAnalysis.com statistics and Barchart technical analysis | August 2, 2026 |
| Market reaction to Q2 | Shares fell as much as 11% in early European trading on July 28, 2026 after the 1% order decline, setting a 52-week low of $23.85 intraday before closing at $25.55 and recovering to $26.30 by July 31 | WSJ, GuruFocus, and StockAnalysis.com price history | August 2, 2026 |
This PHG AI stock analysis is an informational research tool, not investment, legal, tax, or trading advice. Forecast scenarios use available data and assumptions that can be wrong. Prices, technical levels, financial results, legal developments, and regulatory conditions can change quickly. The Q2 2026 margin included a one-time US tariff refund that may not repeat. Verify primary sources and consider professional advice before making an investment decision.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
